PubMed
GHRP-2: a GH secretagogue for clinical use
Bowers CY. J Pediatr Endocrinol Metab. 1997
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 3% · Unfavorable overall 94%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 100–400 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 79% said they felt similar to their last entry, 21% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 180 days · Based on 24 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 14% · Mixed 0% · Unfavorable overall 86%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.4 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Published sources linked on the GHRP-2 and Tirzepatide wiki pages.
PubMed
Bowers CY. J Pediatr Endocrinol Metab. 1997
PubMed
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
FDA Drug Label
Eli Lilly. FDA Drug Label. 2022
PubMed
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021
PubMed
Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024
FDA Drug Label
Eli Lilly. FDA Drug Label. 2023
PubMed
Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023
PubMed
Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025
PubMed
Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026
PubMed
Aronne LJ, Ahmad NN, Fletcher M, et al. JAMA. 2024